AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31531997
Drug: Immunonutrition and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunonutrition and Standard polymeric supplements
Trial: 30848558
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) plus nonbiologic background medication (NBBM)
Trial: 30848558
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus nonbiologic background medication (NBBM)
Trial: 26803169
Drug: SeY-100/d (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SeY-100/d (100 μg Se/day)
Trial: 26803169
Drug: SeY-50/d (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SeY-50/d (50 μg Se/day)
Trial: 26803169
Drug: SeY-200/d (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SeY-200/d (200 μg Se/day)
Trial: 26803169
Drug: SeO-50/d (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SeO-50/d (50 μg Se/day)
Trial: 26803169
Drug: Se supplementation
RxNorm normalized name: selenomethionine Se 75
DrugBank: Selenomethionine Se-75 (DB09400)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Se supplementation (various doses)
Trial: 21519309
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine infusion (1 mg/kg per hour) with patient-controlled analgesia morphine for the first 48 hours after surgery
Trial: 21519309
Drug: Thoracic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural analgesia with patient-controlled analgesia morphine for the first 48 hours after surgery
Trial: 10903240
Drug: montelukast at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: montelukast at 5 mg/d for 2 days
Trial: 9305235
Drug: Mixed weed
RxNorm normalized name: ALLERGENIC EXTRACT MIXED WEEDS INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed weed extract (1:2500 wt/vol to 1:10 wt/vol) administered daily for 12 to 16 weeks with 5.2 mg intranasal cromolyn pretreatment.
Trial: 8454221
Drug: Parenteral hydralazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral hydralazine
Trial: 3096592
Drug: Terfenadine suspension,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine suspension, 30 mg b.i.d.
Trial: 25054430
Drug: Dofetilide (pure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dofetilide (pure hERG potassium channel blocker)
Trial: 17660482
Drug: digoxin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: digoxin (0.5 mg, then 0.25 mg qd on days 2‐7)
Trial: 17660482
Drug: combination vildagliptin/digoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination vildagliptin/digoxin for 7 days
Trial: 10999557
Drug: Levetiracetam (LEV)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam (LEV) 1,000 mg twice daily
Trial: 10999557
Drug: Levetiracetam (LEV)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam (LEV) 2,000 mg twice daily
Trial: 10999557
Drug: Levetiracetam (LEV)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam (LEV) 1,000 mg and 2,000 mg
Trial: 1599635
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate supplementation (1 g for 12 weeks)
Trial: 3830333
Drug: Type 1
RxNorm normalized name: Type 1 H substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type 1 electroconvulsive therapy
Trial: 3830333
Drug: Type 2
RxNorm normalized name: Type 2 H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type 2 electroconvulsive therapy
Trial: 3830333
Drug: Type 3
RxNorm normalized name: Type 3 H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type 3 electroconvulsive therapy
Trial: 24239386
Drug: Hyperfractionated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiation therapy
Trial: 24239386
Drug: Standard radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard radiation therapy
Trial: 18621791
Drug: Bimatoprost twice
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bimatoprost twice daily/once daily
Trial: 21059740
Drug: n-3 polyunsaturated
RxNorm normalized name: Omega-3 (n-3) polyunsaturated fatty acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 polyunsaturated fatty acids (PUFAs) 3 g/day until ECV and 2 g/day thereafter
Trial: 18664159
Drug: Cryosurgery followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cryosurgery followed by diclofenac sodium 3% gel for 90 days
Trial: 8803370
Drug: Nicotine gum
RxNorm normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine gum (2 or 4 mg)
Trial: 23943282
Drug: Topical 0.4
RxNorm normalized name: fluoride topical 0.4% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.4 % glyceryl trinitrate (GTN) ointment every 12 hours for four postoperative weeks
Trial: 23943282
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no GTN ointment)
Trial: 23943282
Drug: Topical 0.4
RxNorm normalized name: fluoride topical 0.4% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.4 % glyceryl trinitrate (GTN) ointment
Trial: 19796735
Drug: High-dose statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose statin therapy initiated pre-discharge
Trial: 20391072
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (CBT) program, 6-week duration
Trial: 1906746
Drug: Prophylactic administration
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic administration of OKT3
Trial: 29170901
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (Phototherapy + EXT)
Trial: 8384658
Drug: Roxithromycin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxithromycin (150 mg every 12 hours for 7 days)
Trial: 29402234
Drug: Structured follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured follow-up by a GP and home care oncology nurse (HON) including a GP consultation before treatment and a minimum of three contacts with the HON during and after treatment.
Trial: 22546175
Drug: Wood smoke
RxNorm normalized name: Wood creosote
DrugBank: Wood creosote (DB13271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wood smoke exposure at 200 μg/m(3)
Trial: 22546175
Drug: Wood smoke
RxNorm normalized name: Wood creosote
DrugBank: Wood creosote (DB13271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wood smoke exposure at 400 μg/m(3)
Trial: 18448442
Drug: 0.625‐mg conjugated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625‐mg conjugated equine estrogens (CEEs)
Trial: 7386802
Drug: Purified allergen
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified allergen preparation
Trial: 28571271
Drug: 0.1% triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% triamcinolone acetonide oral paste thrice daily in tapering doses
Trial: 28571271
Drug: curcumin oral
RxNorm normalized name: curcumin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: curcumin oral gel thrice daily
Trial: 28571271
Drug: curcumin oral
RxNorm normalized name: curcumin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: curcumin oral gel six times daily
Trial: 26451088
Drug: Probiotic preparation
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic preparation inVag(®) administered vaginally for seven consecutive days
Trial: 26451088
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered vaginally for seven consecutive days
Trial: 23339578
Drug: 4.5 g
RxNorm normalized name: Zosyn 4.5 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5 g of larch arabinogalactan preparation (n=101)
Trial: 14965858
Drug: Principal Component
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Principal Component Analysis (PCA) applied on multichannel magnetocardiographic (MCG) recordings in patients with MI.
Trial: 14965858
Drug: Principal Component
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Principal Component Analysis (PCA) applied on multichannel magnetocardiographic (MCG) recordings in patients with VT.
Trial: 14965858
Drug: Principal Component
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Principal Component Analysis (PCA) applied on multichannel magnetocardiographic (MCG) recordings in normals.
Trial: 14965858
Drug: Principal Component
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Principal Component Analysis (PCA) applied on multichannel magnetocardiographic (MCG) recordings in patients with CHD.
Trial: 11001237
Drug: Fixed regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed regimen of 30 mg mirtazapine at bedtime
Trial: 11001237
Drug: Ascending dose
RxNorm normalized name: IODINE 1 kg in 1 kg TOPICAL LIQUID [ASCEND]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending dose regimen of mirtazapine (15 mg to 30 mg at bedtime)
Trial: 11001237
Drug: Both regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both regimens (fixed and ascending dosing)
Trial: 9071932
Drug: bFGF 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bFGF 0.1 mg twice daily
Trial: 3098498
Drug: Levonorgestrel 20
RxNorm normalized name: ethinyl estradiol-levonorgestrel 20 mcg-90 mcg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel 20 mcg/day
Trial: 27825381
Drug: Cornerstone program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cornerstone program (case management, trauma-focused cognitive behavioral therapy, mentoring/peer support, community-based practice, stigma and skill development)
Trial: 24911076
Drug: Biosimilar G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biosimilar G-CSF (Zarzio(®), Sandoz Biopharmaceuticals)
Trial: 24911076
Drug: Originator G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Originator G-CSF (Neupogen(®), Amgen)
Trial: 23158715
Drug: Oral endotracheal
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral endotracheal intubation (OEI)
Trial: 19619073
Drug: Rivastigmine (transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine (transdermal patch)
Trial: 15711943
Drug: Traditional voice
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional voice treatment
Trial: 9449870
Drug: Diethylcarbamazine 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diethylcarbamazine 6 mg/kg
Trial: 9449870
Drug: Diethylcarbamazine 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diethylcarbamazine 6 mg/kg plus ivermectin 400 micrograms/kg
Trial: 360921
Drug: Active drug
RxNorm normalized name: Capillary active drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug therapy (50 mg chlorthalidone, 100 mg chlorthalidone, and 100 mg chlorthalidone plus 0.25 mg reserpine)
Trial: 30921982
Drug: Th1-transforaminal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Th1-transforaminal epidural injection (Th1-TFEI)
Trial: 30921982
Drug: Th1/2-parasagittal interlaminar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Th1/2-parasagittal interlaminar epidural injection (Th1/2-pILEI)
Trial: 22221427
Drug: Formoterol 12
RxNorm normalized name: formoterol 12 mcg inhalation capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol 12 micrograms and Beclomethasone 200 micrograms (HFA; metered-dose inhaler) b.i.d. (FB)
Trial: 19224761
Drug: 6-mercaptopurine (6MP)/methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-mercaptopurine (6MP)/methotrexate (MTX) maintenance therapy
Trial: 19224761
Drug: Longer duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longer duration of oral 6MP/MTX maintenance therapy
Trial: 19224761
Drug: Average 6MP
RxNorm normalized name: 2-Amino 6MP
DrugBank: Tioguanine (DB00352)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average 6MP doses in TPMT wild-type patients
Trial: 17301297
Drug: Intravenous methylprednisolone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone, 30 mg per kilogram of body weight
Trial: 16265829
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (oral and intravenous fluid replacement, NSAIDs, caffeine)
Trial: 16265829
Drug: Epidural blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural blood patch (EBP)
Trial: 11591613
Drug: CEE 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.625 mg and MPA 2.5 mg
Trial: 11591613
Drug: CEE 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.625 mg and MPA 5.0 mg
Trial: 7875113
Drug: Unilateral electroconvulsive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral electroconvulsive therapy (ECT)
Trial: 19783808
Drug: Medication manipulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication manipulation
Trial: 16140028
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid (HA) inhalation (3 ml 0.1% in PBS)
Trial: 16140028
Drug: Placebo inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhalation (3 ml PBS)
Trial: 16140028
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid (HA) inhalation
Trial: 1306735
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg 4-HPR daily for 52 weeks
Trial: 31970796
Drug: Whole blood
RxNorm normalized name: Whole blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole blood treatment
Trial: 31970796
Drug: Component therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Component therapy (current standard of care)
Trial: 31970796
Drug: Relative risk
RxNorm normalized name: (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relative risk of whole blood compared to component therapy
Trial: 30663629
Drug: Outpatient individual
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Outpatient individual treatment adherence
Trial: 16754834
Drug: Low-dose ketamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ketamine (100 ng/mL of plasma)
Trial: 16754834
Drug: High-dose ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ketamine (200 ng/mL of plasma)
Trial: 1672841
Drug: Antianginal drugs
RxNorm normalized name: ANTIANGINALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antianginal drugs (beta-blockers, calcium antagonists, nitrates, alone or in various combinations)
Trial: 22772335
Drug: Dopamine D₃
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine D₃ receptor antagonist, GSK598809 (175 mg)
Trial: 18330846
Drug: Lamotrigine (LTG)
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine (LTG) monotherapy, mean maintenance dose 217.2 mg/day
Trial: 16322140
Drug: Multisystemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multisystemic therapy (MST) for approximately 6 months
Trial: 10408847
Drug: Granisetron 3
RxNorm normalized name: granisetron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron 3 mg intravenous
Trial: 10408847
Drug: Prednisolone 25
RxNorm normalized name: prednisolone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 25 mg oral plus metopimazine 30 mg oral
Trial: 8877895
Drug: Menatetrenone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menatetrenone (15 mg) after meal A (8.8 g fat)
Trial: 8877895
Drug: Menatetrenone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menatetrenone (15 mg) after meal B (20.0 g fat)
Trial: 8877895
Drug: Menatetrenone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menatetrenone (15 mg) after meal C (34.9 g fat)
Trial: 8877895
Drug: Menatetrenone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menatetrenone (15 mg) after meal B (20.0 g fat) without lunch
Trial: 8877895
Drug: Menatetrenone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menatetrenone (15 mg) after meal D (53.8 g fat)
Trial: 1892404
Drug: Systemic antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antibiotics from immediately after surgery until the third day (Group B)
Trial: 1892404
Drug: Local sterile
RxNorm normalized name: Steril-Eyes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local sterile antibiotic powder sprinkled into the wound during surgery (Group C)
Trial: 1892404
Drug: Systemic antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antibiotics from 2 days before surgery until the second day after surgery (Group D)
Trial: 1892404
Drug: No antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotics (Group A)
Trial: 30866108
Drug: Detomidine (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detomidine (0.01 mg/kg bwt)
Trial: 30866108
Drug: Detomidine (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detomidine (0.01 mg/kg bwt) + Butorphanol (0.02 mg/kg bwt)
Trial: 30866108
Drug: Saline (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (0.9% solution, 10 mL)
Trial: 28604151
Drug: Diltiazem-Hydrochloride (DTZ)
RxNorm normalized name: Diltiazem Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem-Hydrochloride (DTZ) in sustained-release matrix tablets
Trial: 27214088
Drug: Eprosartan (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan (3 and 10 μg/kg/min for 15 min per dose)
Trial: 27214088
Drug: Eprosartan (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan (3 and 10 μg/kg/min for 15 min per dose) with low sodium diet
Trial: 27214088
Drug: Eprosartan (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan (3 and 10 μg/kg/min for 15 min per dose) with Ang II co-infusion (1 ng/kg/min)
Trial: 25075176
Drug: Lidocaine 2%
RxNorm normalized name: LIDOCAINE 2% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2% (5 mL) delivered by JetPeel™‐3 followed by multiple injections of BTX‐A (100 units)
Trial: 25075176
Drug: Lidocaine 2%
RxNorm normalized name: LIDOCAINE 2% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2% (5 mL) and BTX‐A (50 units) delivered together by JetPeel™‐3
Trial: 25075176
Drug: Lidocaine delivered
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine delivered by JetPeel™‐3 followed by multiple BTX‐A injections
Trial: 18035201
Drug: Lamotrigine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine (400 mg daily, titrated over 8 weeks)
Trial: 7718463
Drug: 2% ketoconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% ketoconazole shampoo (twice weekly for 2-4 weeks)
Trial: 7718463
Drug: 2% ketoconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% ketoconazole shampoo (once-weekly, once every other week, alternating with placebo)
Trial: 7718463
Drug: Placebo shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo shampoo (once-weekly)
Trial: 7718463
Drug: Active/placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active/placebo group (alternating treatment)
Trial: 6112386
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid plus dipyridamole (1050 mg + 150 mg/day, group A)
Trial: 6112386
Drug: Pentoxifylline (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (1200 mg/day, group B)
Trial: 26338693
Drug: Aripiprazole (5‐30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (5‐30 mg/d)
Trial: 26338693
Drug: Risperidone (1‐6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (1‐6 mg/d)
Trial: 23672956
Drug: Subcutaneous hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subcutaneous hydrocortisone (100 mg)